1. Home
  2. RAYA vs PPCB Comparison

RAYA vs PPCB Comparison

Compare RAYA & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Erayak Power Solution Group Inc.

RAYA

Erayak Power Solution Group Inc.

HOLD

Current Price

$4.11

Market Cap

2.5M

ML Signal

HOLD

PPCB

Propanc Biopharma Inc.

HOLD

Current Price

$0.09

Market Cap

2.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAYA
PPCB
Founded
2019
2007
Country
China
Australia
Employees
N/A
2
Industry
Metal Fabrications
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
RAYA
PPCB
Price
$4.11
$0.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.1M
5.8M
Earning Date
04-17-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.95
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.09
52 Week High
$10.14
$10.69

Technical Indicators

Market Signals
Indicator
RAYA
PPCB
Relative Strength Index (RSI) 67.36 34.44
Support Level $3.35 N/A
Resistance Level $4.17 $0.13
Average True Range (ATR) 0.48 0.01
MACD 0.06 0.00
Stochastic Oscillator 51.61 8.10

Price Performance

Historical Comparison
RAYA
PPCB

About RAYA Erayak Power Solution Group Inc.

Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: